Mabworks Biotech
Beijing, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
An antibody-focused biotech developing novel mAbs and bispecifics for cancer and immunology.
OncologyImmunologyAntibodies
Technology Platform
An integrated antibody discovery and engineering platform for generating high-affinity monoclonal and multifunctional bispecific antibodies.
Opportunities
Partnerships with larger pharma for clinical development and ex-China rights could provide non-dilutive funding and validation.
Risk Factors
Pipeline assets may fail to demonstrate differentiation from established or emerging standard-of-care treatments.
Competitive Landscape
Enters a highly saturated market for antibody therapies, competing with dozens of similar-sized Chinese biotechs and global giants on scientific innovation.